UK Biobank Study Links Postmenopausal Hormone Therapy to Lower Dementia Risk

A new UK Biobank study published in Alzheimer’s & Dementia reveals that postmenopausal women who start hormone replacement therapy at a certain age may have a lower dementia risk, though clinicians emphasize the observational data does not prove a direct preventive cause.

Postmenopausal women who begin hormone replacement therapy within a specific age window may see a notable reduction in their long-term cognitive risks. The research, which analyzed health data from 183,450 postmenopausal women with an average age of 60, tracked participants over a 13-year follow-up period across the United Kingdom. Investigators determined that overall usage of the therapy aligned with a roughly 10% lower risk of all-cause dementia and a 16% lower risk specifically for Alzheimer’s disease. Fox News reported that the research also failed to evaluate safety measures or adverse effects linked to HRT, adding that individuals taking hormone therapy might vary from non-users through distinct factors influencing dementia likelihood, including general well-being, daily habits, or medical care availability.

Age Thresholds and Menopause Types in UK Biobank Data

The protective association was not distributed evenly across all participants. Researchers found that the lowered risk was strongest among women who initiated hormone therapy between the ages of 46 and 56. Strong associations also appeared among individuals who underwent surgical menopause. Conversely, starting the therapy after age 56 showed no reduction in dementia risk.

Photo: Worldjournal

Menopausal Hormone Therapy: Oral Estrogen Linked to Higher Blood Clot Risk, Transdermal Safe

Despite the broad dataset, the study carried notable methodological limitations. Because the research relied on observational data rather than a clinical trial, it established correlation rather than direct causation. The analysis did not capture detailed information regarding specific hormone types, exact dosages, or administration routes, and the cohort largely comprised individuals of European ancestry with favorable socioeconomic status. Fox News noted that most of the people in the study tended to be better off financially, meaning the findings may not apply equally to people from other populations.

Transient Ischemic Attacks Linked to Higher Long-Term Dementia Risk

Clinical Perspectives on Symptoms and Vascular Risk

Medical experts urge caution against adopting the treatment solely for cognitive preservation. Dr. Alexa Fiffick, a board-certified family medicine physician and founder of Concierge Medicine of Westlake in Cleveland, Ohio, observed that current findings align seamlessly with earlier research.

Photo: nature.com

At the same time, Fiffick pointed out via Fox News that younger menopausal transitions or specific genetic predispositions, such as carrying the APOE ε4 genotype, may alter the calculus for individual patients. Existing medical data also links severe menopausal symptoms like hot flashes and night sweats to vascular brain changes.

Weighing Individual Safety Profiles and Administration Routes

Hormone therapy carries inherent medical risks that vary significantly depending on how the medications are delivered. Oral estrogen formulations carry an elevated risk of blood clots, whereas transdermal alternatives such as skin patches, gels, and creams do not appear to carry that same hazard. Different regimens can also influence breast activity, inflammatory markers, and cardiometabolic health according to Fox News.

Early retirement increases dementia and alcohol use disorder risks

Future Clinical Trials and Research Directions

To move past observational limits, UK researchers intend to launch randomized controlled trials designed to isolate specific variables. Upcoming investigations will evaluate estrogen-only versus combined hormone formulations, exact dosages, administration routes, treatment durations, and the potential influence of the APOE genotype.

As noted by Fox News, the U.K. researchers plan to conduct randomized controlled trials to confirm that HRT reduces dementia risk.